To understand the nature of structural defects that produce osteogenesis irnperfecta (01), the modes of inheritance of the several forms of the disease, and the effects of specific mutations on the behavior of the type I collagen molecule, we have developed a general strategy for analyzing the basic molecular defects which produce the phenotype. The genes encoding the two chains of the type I collagen molecule are structurally complex,'.* and the proteins are large and internally repetitive?' making analysis of mutations at either the DNA or protein level difficult. The al( I) and a2( I) chains which make up the type I collagen heterotrimer are encoded by the 18 kilobase (kb) 
COLlAl'*' and 38 kb COL1A26 genes, respectively. Many methods have been used in the analysis of mutations which produce osteogenesis irnperfecta, including a variety of genomic cloning strategies,'-'2 cDNA ~loning,'~~'' protein sequence determinat i~n , '~' '~ mRNA sequence determination,' S1 nuclease cleavage,16 RNase cleavage," and R-loop analysis.'* In general, each study is tailored to the biochemical phenotype of the type I collagen molecules produced by the cell strain. Our goal has been to develop general strategies for analyzing mutations so that the same methods can be applied to the determination of the structure of mutations in many cell strains.
We have developed strategies by which most or all of the genes of interest can be isolated. DNA sequence analysis by localization of a structural alteration in the type I collagen molecule determined at the protein level is used to characterize the mutation. There are several advantages to this approach. Because the DNA fragments isolated are large and carry most of the gene of interest, the basic strategy will be useful in analyzing a wide variety of mutations. The fragments contain polymorphic restriction sites, so alleles from heterozygotes can be distinguished after isolation. When the proper haplotypes are present, the parental origin of mutation can also be determined.
THE COLlA2 GENE
Most of the exons of the 38 kb COLlA2 gene are contained within a 27 kb BamHI restriction fragment. Patient DNA is digested with BamHI and size-fractionated. The DNA is ligated into the unique BamHI site of cosmid pRK311I9 and packaged into lambda phage heads in v i m z o Recombinants carrying the COLlA2 gene are identified by colony hybridization." Typically one positive clone per 3-15 x lo3 colonies is seen.
The isolated BamHI fragment contains 4 common polymorphic restriction sites2"2' that have been used to distinguish alleles from individuals heterozygous at one of the sites. The frequencies of the 4 polymorphisms are such that heterozygosity is likely in most individuals. In families with dominantly inherited 01, linkage of a particular allele to the phenotype can also be determined.
From cDNA sequences,26." genomic DNA sequences,6.28 and genomic restriction maps: we have developed a map that relates the linear arrangement of the protein (represented as cyanogen bromide (CB) cleavage fragments) to that of the exons in the gene (FIG. 1) . The 27 kb BamHI fragment carries exons that encode the carboxylterminal 85% of a2(I)CB4, all of a2(I)CB3-5, and all of the C-propeptide.
We used the strategy to isolate alleles from an infant with 01 type I1 carrying a 4.5 kb deletion within one COLlA2 allele." The alleles were isolated, distinguished by restriction analysis, and heterozygosity at the polymorphic EcoRI site was used to establish that the deletion occurred in the paternally-derived allele. DNA sequence determination indicated that the deletion removed the 7 exons that encode amino acids 586-765 of the triple-helical domain. There was no homology between the endpoints of the deletion, suggesting a nonhomologous recombination mechanism. The endpoints of the deletion were located in introns, indicating that the protein product of the deletion allele should have an intact Gly-X-Y repeat. Even so, type I collagen molecules containing the short chain had excessive posttranslational modification (overmodification) amino-terminal to the deletion junction, were thermally unstable, and were poorly secreted, suggesting that elements of type I collagen primary structure beyond the Gly-X-Y repeat are important for triple-helix stability and mo-lecular function. The characterization of this mutation also indicates that lethal mutations are not restricted to the COLlAl gene.
We have also used this strategy to characterize a mutation which produces the mild to moderate 0 1 type IV phenotype." Linkage analysis using restriction fragment length polymorphic markers has demonstrated linkage of the phenotype to the COL 1A2 gene in several fa mi lie^?^.'^ Biochemical defects including small deletions in the a2(I) chains of affected individual^^*^' have supported the linkage data. We studied a small family in which the phenotype was inherited in an autosomal dominant fashion. Skin fibroblasts from affected individuals produced a population of normal type I collagen molecules and a population of molecules in which overmodification extended along the entire triple-helical region. Isoelectric focusing of peptides of type I collagen prepared by digestion with mammalian collagenase and cleavage with cyanogen bromide demonstrated a basic charge shift in a population of the a2(I)CBSB peptide fragments in affected family members, linking the phenotype to the COLlA2 gene. Analysis of COLlA2 restriction fragment length polymorphisms indicated that the phenotype associated with the RsaI( -) allele. Alleles were isolated from an affected individual, distinguished by restriction analysis, and the RsaI( -) allele was selected for DNA sequence analysis. The a2(I)CBZB peptide fragment is encoded by a 3.0 kb XhoI-XbaI restriction fragment which was subcloned into M13mp19. DNA sequence determination showed that the basic charge shift resulted from a single nucleotide change which substituted an arginine for the last glycine (residue 1012) of the triple helix. This result indicated that substitutions for glycine in the a2( I) chain can have milder clinical consequences than analogous defects in the al (1) chain.
THE COLlAl GENE
The entire 18 kb COLlAl gene except for the last 12 codons and the 3' untranslated region is contained within a ca. 23 kb EcoRI fragment. Using a similar strategy to that developed for the COLlA2 gene, we have isolated this fragment using cosmid vector pLAFRl .32 The fragment contains the only known intragenic polymorphic restriction site:3 which allows alleles from heterozygotes to be distinguished. We used cDNA sequences,)4 genomic DNA (D. H. Cohn, unpublished; R. E. Gelinas, unpublished) , and genomic restriction to relate the COL 1Al gene structure to the al(1) protein structure (FIG. 2) . The genomic DNA sequence information known for the COLlAl gene has facilitated efficient strategies for DNA sequence analysis. We used the genomic sequence information to design and synthesize exon-specific primers for some regions of the gene.q The primers are a series of 2Omers which anneal to each intron near the intron-exon junctions. The primers are used in chain termination DNA sequence analysis to rapidly assay the exons encoding a particular region of the protein. As an example, for the 2 kb region of the gene encoding the 192 residues of al(I)CB6, 9 primers have been used to determine the sequence of each exon. 
PERSPECTIVES
We have developed general strategies to isolate the genes encoding type I collagen for use in determining the structures of mutations which produce osteogenesis imperfects. Characterization of mutations has allowed us to test hypotheses relating to the determinants of triple-helix stability, the distinct functions of the al(1) and a2( I) chains, and the relationship between mutational structure and clinical phenotype.
While exceedingly useful, the methods described here cannot be applied to cell strains from all 0 1 patients. Some cell strains do not show an obvious biochemical phenotype. In those that do, where mutations fall outside the identified fragment, alternative cloning strategies will be necessary. In sporadic cases of 01, assigning the mutation to COLlAl or COLlA2 may not be easy and there may be cases where the mutation does not reside in either gene. Several methods are available to make gene assignments for cells harboring apparent point mutations. At the protein level, isoelectric foc~sing'~*'~ of cyanogen bromide peptide fragments of type I collagen for those mutations which produce a charge change in a type I collagen peptide fragment'"" is the best method. At the RNA level, cleavage with RNase at single base mismatches in mRNA-cDNA duplexes3* should also be useful. The RNase cleavage method will also detect deletions too small to be seen at the protein level. Where there is a family history of the disease, linkage analysis combined with analysis of type I collagens produced by cells from affected family members can be used. While none of these methods alone can be used to determine the exact nature of the mutations, in combination with the gene isolation and DNA sequence determination methods outlined above, they can provide a powerful and rapid method for the systematic characterization of a number of interesting mutations.
As additional mutations are characterized, a relationship between the nature of the mutation and the clinical outcome is expected to emerge. The results should begin to dissect functional domains within the type I collagen molecule and allow us to derive new hypotheses regarding the roles this protein assumes in the extracellular matrix. 
